Seridopidine

CAS No. 883631-51-4

Seridopidine( —— )

Catalog No. M34708 CAS No. 883631-51-4

Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 333 In Stock
10MG 504 In Stock
25MG 816 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG 2967 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Seridopidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
  • Description
    Seridopidine (ACR343) is a modulator of dopaminergic activity that is used as an oral therapy for schizophrenia, Parkinson's disease, and Tourette's syndrome.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    Dopamine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    883631-51-4
  • Formula Weight
    285.38
  • Molecular Formula
    C14H20FNO2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    S(C)(=O)(=O)C=1C=C(C=C(F)C1)C2CCN(CC)CC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • BP 897

    2-Naphthalenecarboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]- is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist.

  • carfenazine

    carfenazine targets the Dopamine receptor and is used for schizophrenia research.

  • GSK598809

    GSK598809 (GSK-598809) is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.